DocWire News Editors

DocwireNews

According to research presented at the annual meeting, patients with gout who fail to reach a serum urate target of 6 mg/dL have a higher risk for mortality. The presenters encouraged rheumatologists to “treat to target” in patients with gout in order to improve chances of survival.
A painful form of arthritis, gout occurs when excess uric acid, a waste product, collects in the body and leads to urate crystals in and around joints. The crystals may settle and form tophi that appear under the skin. Gout occurs more often in men, post-menopausal women, and people with kidney disease. Patients can lower serum urate levels and manage gout with diet and lifestyle modifications, as well as medications.
Gout is associated with a higher risk of cardiovascular events and death. Research has shown that increasing severity is associated with risk of death, as reflected in the number of tophi. Previous research also has shown that serum urate levels at baseline and during therapy, flares, and comorbidities all are risk factors for mortality. Therefore, the researchers who presented at the annual meeting assessed whether lowering serum uric acid levels to less than 6 mg/dL would improve risk.
The prospective, follow-up cohort study included 1,193 patients treated at a gout clinic from 1992 to 2017. Of the overall study population, 85 percent had a confirmed diagnosis of gout via microscope or ultrasound, and all patients had had at least one follow-up visit, during which serum uric acid levels were monitored. The study used average serum uric acid level until stabilization as the primary exposure, defined as less than 6 mg/dL versus more than 6 mg/dL.
Patients’ mean serum uric acid level at baseline was 9.1 mg/dL, and 16.3 percent of patients maintained serum uric acid levels of 6 or more mg/dl despite treatment. A total of 158 deaths occurred (a 13 percent overall mortality rate). Twenty-four percent of cases were lost to follow-up.
The mortality rate was significantly higher for patients whose serum uric acid level was greater than 6 mg/dL. After adjusting for age, sex, previous cardiovascular events, and baseline serum uric acid concentration, the researchers found that a serum uric acid level of 6 mg/dL or higher was associated with higher mortality risk. They concluded, consequently, that failure to reach a target serum urate level of 6 mg/dL is an independent predictor of mortality in patients with gout.
Coauthor Fernando Perez Ruiz, MD, PhD, of the Hospital Universitario Cruces in Spain, a coauthor on the study ,urged meeting participants to use a treat-to-target approach for hyperuricemia in gout, rather than treat-to-flare.

According to research presented at the annual meeting, patients with gout who fail to reach a serum urate target of 6 mg/dL have a higher risk for mortality. The presenters encouraged rheumatologists to “treat to target” in patients with gout in order to improve chances of survival.A painful form of arthritis, gout occurs when excess uric acid, a waste product, collects in the body and leads to urate crystals in and around joints. The crystals may settle and form tophi that appear under the skin. Gout occurs more often in men, post-menopausal women, and people with kidney disease. Patients can lower serum urate levels and manage gout with diet and lifestyle modifications, as well as medications.Gout is associated with a higher risk of cardiovascular events and death. Research has shown that increasing severity is associated with risk of death, as reflected in the number of tophi. Previous research also has shown that serum urate levels at baseline and during therapy, flares, and comorbidities all are risk factors for mortality. Therefore, the researchers who presented at the annual meeting assessed whether lowering serum uric acid levels to less than 6 mg/dL would improve risk.The prospective, follow-up cohort study included 1,193 patients treated at a gout clinic from 1992 to 2017. Of the overall study population, 85 percent had a confirmed diagnosis of gout via microscope or ultrasound, and all patients had had at least one follow-up visit, during which serum uric acid levels were monitored. The study used average serum uric acid level until stabilization as the primary exposure, defined as less than 6 mg/dL versus more than 6 mg/dL.Patients’ mean serum uric acid level at baseline was 9.1 mg/dL, and 16.3 percent of patients maintained serum uric acid levels of 6 or more mg/dl despite treatment. A total of 158 deaths occurred (a 13 percent overall mortality rate). Twenty-four percent of cases were lost to follow-up.The mortality rate was significantly higher for patients whose serum uric acid level was greater than 6 mg/dL. After adjusting for age, sex, previous cardiovascular events, and baseline serum uric acid concentration, the researchers found that a serum uric acid level of 6 mg/dL or higher was associated with higher mortality risk. They concluded, consequently, that failure to reach a target serum urate level of 6 mg/dL is an independent predictor of mortality in patients with gout.Coauthor Fernando Perez Ruiz, MD, PhD, of the Hospital Universitario Cruces in Spain, a coauthor on the study ,urged meeting participants to use a treat-to-target approach for hyperuricemia in gout, rather than treat-to-flare.

Izzah Nawaz

IBD on the Rise: Canterbury Study Warns of Growing Health Burden

Gastroenterology

Jordana Jampel

Paternal Distress Linked to Child Development Delays

Neurology

Comparing Diets for IBS Relief: Mediterranean Versus Low-FODMAP

Latest News

Research Identifies Independent Risk Factor for Mortality in Patients with Gout

ACR 2018 Conference

According to research presented at the annual meeting, patients with gout who fail to reach a serum urate target of 6 mg/dL have a higher risk for mortality. The presenters ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Diabetes

Obesity

Metabolic Care Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe